2014 Archive
VCU researchers show experimental drug could enhance the effectiveness of existing multiple myeloma and myeloid leukemia therapies
A pre-clinical study led by Virginia Commonwealth University Massey Cancer Center and Department of Internal Medicine researchers suggests that an experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies. The study, recently published in the journal Molecular Cancer Therapeutics, showed that dinaciclib disrupted a cell survival mechanism known as the unfolded protein response (UPR). Without the UPR, multiple myeloma and myeloid leukemia cells were unable to combat damage caused by some anti-cancer agents.
Supporting the survivor: tips for caregivers
Whether they are spouses, partners, children, relatives or friends, caregivers play a vital role in a patient’s treatment and recovery. The role of the caregiver changes as the patient’s needs change. New challenges may arise during phases of the patient’s journey, which include diagnosis, treatment, at-home care and recovery. Below are a few helpful tips on how caregivers can support the survivor during these phases.
VCU researcher Paul Fisher honored as “scientist of the year” by Governor Terry McAuliffe
Newly elected Governor Terry McAuliffe presented Paul B. Fisher, M.Ph., Ph.D., the Virginia’s Outstanding Scientist of 2014 award at the Science Museum of Virginia’s General Assembly Reception on Thursday, January 16. Fisher was one of two scientists who received this year’s award. He was recognized for his pioneering work in the field of molecular biology and the translation of his research from “bench to bedside.”
The $125 billion question: how will the ACA affect cancer survivors?
In 2010, the total cost of cancer care in the United States reached $125 billion. Cancer patients are also living longer today, which is further increasing the cost of their continued care. As the health insurance exchanges have opened and heated debate about the Affordable Care Act (ACA) continues, many questions remain, including the $125 billion question: “How will the ACA affect the most expensive disease: cancer?”
